stonks4u
Sign up free
RCKT logo

RCKT Rocket Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$3.47
+0.13 (+3.89%)

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, charact…

Market Cap: $378.90Mrocketpharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

140
140
Aug 10Aug 11

Quote

Day Range
$3.27 – $3.50
52-Week Range
$2.53 – $5.45
Volume
$1.16M
Market Cap
$378.90M
50-Day Avg
$3.35
200-Day Avg
$3.56
Prev Close
$3.34
Open
$3.33

Valuation & Ratios

P/E Ratio
-1.75
EPS
$-2.01
P/B Ratio
1.41
P/S Ratio
0.00
Debt/Equity
0.09
Current Ratio
6.38
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-80.5%
Return on Assets
-67.5%
FCF Yield
-48.8%
EV/EBITDA
-1.60

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-223.12M$-2.01
2024$0.00$-258.75M$-2.73
2023$0.00$-245.59M$-2.92
2022$0.00$-221.86M$-3.26
2021$0.00$-169.07M$-2.68

Social Signal Score

91
5d
91
2 mentions
—
30d
91
2 mentions
—
60d
91
2 mentions
—
90d
91
2 mentions
—
news: 2

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.41 per share

5of 7 quarters beat consensus

Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$1.08 vs $0.86beat
  • Thu, May 7$-0.42 vs $-0.41miss
  • Thu, Feb 26$-0.38 vs $-0.42beat
  • Thu, Nov 6$-0.45 vs $-0.48beat
  • Thu, Aug 7$-0.59 vs $-0.57miss
  • Thu, May 8$-0.56 vs $-0.59beat

Estimates and results for RCKT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

RCKThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newszacks.com·3d ago·Positive

    Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

    View source ↗
  • Newsbusinesswire.com·4d ago·Positive

    Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened R

    View source ↗